鉴定与心力衰竭中SUMO修饰相关的生物标志物
Zhe Chen1, Jin Zhao2, Na Xiao1
1Department of Cardiology, Hebei Medical University Third Hospital, Shijiazhuang, Hebei Province, PR China.
Medicine
|November 5, 2025
概括
小型乌比基相关修饰剂 (SUMO) 在心力衰竭 (HF) 中起着治疗作用. 研究人员确定PSME4和CYLD是用于HF诊断和潜在治疗标的关键SUMOylation相关生物标志物.
科学领域:
- 生物化学 生物化学
- 基因组学就是基因组学.
- 心血管研究研究心血管研究
背景情况:
- 小型乌比基相关修饰剂 (SUMO) 在心力衰竭 (HF) 中具有治疗潜力,但其在HF中的调节机制仍然不清楚.
- 了解SUMOylation的作用对于开发新的HF疗法至关重要.
研究的目的:
- 为了确定心力衰竭 (HF) 的与SUMOylation相关的生物标志物.
- 阐明高频中SUMOylation的基本机制和监管网络.
- 探索针对已识别的生物标志物的潜在治疗剂.
主要方法:
- 利用单个样本基因组丰富分析 (ssGSEA) 和权重基因共同表达网络分析 (WGCNA) 来识别与SUMO修饰得分相关的基因模块.
- 采用机器学习算法 (LASSO,SVM-RFE) 来选来自高频差异表达基因 (DEGs) 的关键基因.
- 使用接收器操作特征 (ROC) 曲线和外部表达数据验证的生物标志物显著性.
- 使用比较毒基因组学数据库 (CTD) 构建调控网络 (lncRNA-miRNA-生物标记,TFs-生物标记-miRNA) 和预测相关疾病和药物.
主要成果:
- 确定了8个关键基因与HF中的SUMOylation相关,其中PSME4和CYLD显示出显著的差异表达和诊断潜力.
- 通过ROC分析和外部验证,PSME4和CYLD被证实是HF的优秀预测者.
- 基因组丰富分析 (GSEA) 表明PSME4和CYLD参与细胞周期和溶酶体功能.
- 建立了监管网络,并预测了PSME4和CYLD与其他疾病 (如药物诱导的肝损伤) 的潜在关联,并确定了CR845作为向CYLD的潜在治疗剂.
结论:
- PSME4和CYLD被确定为心力衰竭 (HF) 中的新型SUMOylation相关生物标志物.
- 这些生物标志物为HF病原体和潜在的诊断和治疗策略提供了新的见解.
- 这项研究为进一步调查基于SUMOylation的HF干预措施提供了基础.
相关概念视频
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
529
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
529
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
777
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
777
01:29Heart Failure II: Pathophysiology
699
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
699
01:17Pathophysiology of Heart Failure
2.8K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.8K
01:30Heart Failure V: Medical Management
208
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
208
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
909
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
909